27 results
UPLOAD
KA
Kineta Inc
26 Sep 22
Letter from SEC
12:00am
conflict of
interest and whether the
same individuals were engaged to perform the advisory services. To the
extent you have
not done so … . Additionally, please include a risk factor in the risk
factors section discussing
the risks to investors related to this potential conflict
CORRESP
KA
Kineta Inc
3 Oct 22
Correspondence with SEC
12:00am
. and Kineta, Inc. for this transaction. Please revise to clarify at what point the parties were made aware of the potential conflict of interest and whether … discussing the risks to investors related to this potential conflict of interest.
Response to Comment No. 4. The Company respectfully advises the Staff
8-K
EX-10.6
KA
Kineta Inc
30 Dec 20
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
4:44pm
who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company … have reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of such defense, or (C
S-4/A
EX-10.24
KA
Kineta Inc
28 Oct 20
Registration of securities issued in business combination transactions (amended)
4:59pm
person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company … shall have reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of such defense, or (C
S-4/A
EX-10.22
b7l4bgutf n48r6s8
28 Oct 20
Registration of securities issued in business combination transactions (amended)
4:59pm
8-K
EX-10.2
mkg9z9b1rn6o1
15 Dec 20
Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with Proteostasis
7:34am
425
EX-10.2
b875w55py2hhnihia377
15 Dec 20
Business combination disclosure
7:32am
8-K
EX-10.5
cutrrub9zyehjzcy
30 Dec 20
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
4:44pm
8-K
EX-2.7
hpskftdiavoaf
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-1.1
jt7 h7t7mn42gt4kwuc
24 Oct 18
Entry into a Material Definitive Agreement
4:28pm